Safety monitoring parameters: Gastrointestinal tolerance: Keep a symptom diary during the first 8 weeks, noting severity and duration of nausea, vomiting, or diarrhea Hydration status: Monitor for signs of dehydration, especially if experiencing gastrointestinal side effects Abdominal symptoms: Report persistent or severe abdominal pain promptly for evaluation of potential pancreatitis or gallbladder disease Renal function: Assess at baseline and periodically per ADA guidelines (at least annually
The gastrointestinal symptoms result from tirzepatide's mechanism of slowing gastric emptying and are dose-dependent, which is why gradual dose escalation is recommended
These often improve with time and dietary adjustments
Cancer risk Using a GLP-1 might help lower cancer risk
Its cofactors are TPP bound to E1, lipoic acid covalently bound to lysine on E2 which accepts the hydroxyethyl carbanion from TPP as an acetyl group, coenzyme A which is substrate for E2 and accepts the acetyl group from it, FAD bound to the E3 subunit reduced by lipoamide and NAD which is substrate for E3 and reduced by FADH2 [64]
In practice, the changes in blood pressure can be significant
